tbuckley/cabot-search huggingface dataset:
Effectiveness of an advance care planning patient navigator on advance directive completion by electronic versus staff-based referrals at a major cancer hospital.
Authors: Gayle Ito-Hamerling, Lindsay Emanuel, Finly Zachariah
Journal: Journal of Clinical Oncology (2017)

20 Background: Advance Care Planning (ACP) is a central component of patient-centered care, helping ensure patient values and preferences guide clinical decisions. Patient navigators have been utilized effectively in healthcare for numerous roles, and more recently for ACP. At City of Hope National Medical Center (COH), an ACP-focused navigator was hired to support patients, families, and staff with Advance Directive (AD) notarization and primary ACP conversations. Methods: The Department of Supportive Care Medicine at COH with significant institutional collaboration and administrative support created a patient-centered ACP program and marketing campaign, called “Plan Today for Tomorrow.” In 2016, an ACP navigator joined the team to facilitate AD completion. Referral to the ACP navigator occurred either through staff endorsement and/or the institution’s technological screening platform deployed in a majority of COH outpatient clinics. Staff referrals came from physicians, clinical social workers, nurses, or from the Sheri &amp; Les Biller Patient and Family Resource Center. Prior to the ACP navigator, all referrals were addressed by Clinical Social Workers (CSWs). Results: In a review of 14 months of data, the ACP navigator followed up on 1,125 referrals, 574 were from staff, while 551 were from the institutional tablet-based screening platform. Follow-up on staff referrals resulted in an 86% AD completion rate. Follow-up on tablet-based screening resulted in a 23% AD completion rate. Conclusions: The presence of an available onsite ACP-focused navigator was more effective in facilitating AD completion of staff generated AD referrals as compared to AD completion of tablet-based patient screening AD referrals. The presence of the ACP navigator to facilitate AD completion decreased workload for CSWs, creating increased opportunity for CSWs to work at the top of their professional license. Further work is needed to increase the effectiveness of AD completion from tablet-based screening referrals.
Abstract 14511: How Effective is Blood Pressure Reduction Techniques in Lowering High Blood Pressure Readings in Worksite Health Fair Screenings
Authors: Sankalp Das, Maribeth Rouseff, Henry E Guzman, April S Weatherly, Alena C Costume, Cynthia Gilliam, Virginia Lehn, Shoshana Sherriff, Thinh H Tran, Amett Pino, Brian Betancourt, Erin Leigh, Francisco Jou, Georgelena Saborio, Ivan Saavedra, Jim Cleary, Lynn McCauley, Mary Desimone, Matthew Romney, Natalie D Castro, Terry C Ochoa, Timothy Katz, Towanda Keys, Khurram Nasir
Journal: Circulation (2016)

Introduction: Standard protocol for measuring blood pressure in adults is to have them sit and relax for 5-10 minutes before taking their blood pressure. However, when doing screenings at a workpla...
A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
Authors: D. Fujimoto, T. Yokoyama, H. Yoshioka, Y. Demura, K. Hirano, T. Kawai, R. Kagami, T. Ishida, K. Tomii, M. Akai, M. Hirabayashi, T. Nishimura, Y. Nakahara, Y.H. Kim, K. Yoshimura, T. Hirai
Journal: Annals of Oncology (2017)
Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)
Authors: M. Tamiya, A. Hata, N. Katakami, R. Kaji, T. Yokoyama, K. Toshihiko, T. Inoue, H. Kimura, Y. Yano, D. Tamuta, S. Morita, S. Negoro
Journal: Annals of Oncology (2017)
LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410
Authors: Martin van den Bent, Marica Eoli, Juan Manuel Sepulveda, Marion Smits, Annemiek Walenkamp, Jean-Sebastien Frenel, Alba A Brandes, Paul Clement, Pim French, Hendrikus Dubbink, Johan Kros, Michael Weller, Olivier Chinot, Filip de Vos, Nicolas Whenham, Paul Sanghera, Jim Looman, Ho-Jin Lee, Jan-Peter de Geus, Sarah Nuyens, Maarten Spruyt, Joana Brilhante, Thierry Gorlia, Vassilis Golfinopoulos
Journal: Neuro-Oncology (2017)

Depatux-m is a tumor-specific antibody-drug-conjugate consisting of antibody (ABT-806) bound to the toxin monomethylauristatin-F. We investigated depatux-m in EGFR-amplified recurrent glioblastoma (40–50% of glioblastoma). EORTC-1410-BTG (NCT02343406) is a randomized open label phase II study. Eligible were patients with centrally confirmed EGFR-amplified glioblastoma at first recurrence after temozolomide chemo-irradiation, occurring ≥3 months after radiotherapy. After stratification for WHO status and time of relapse (<16 or ≥16 weeks after the first day of the last temozolomide cycle), patients were randomized to either a) treatment with depatux-m 1.0 mg/kg every 2 weeks intravenously, or b) the same treatment combined with temozolomide 150–200 mg/m2 day 1–5 every 4 weeks, or c) either lomustine or temozolomide (TMZ/LOM) depending on the time of relapse. Primary endpoint was overall survival (OS); 240 patients/170 events were needed to detect a HR reduction of 0.54 in the depatux-m arms. Between March 2015 and July 2016 260 patients were randomized. With 199 events observed, for the primary comparison of depatux-m in combination with TMZ versus TMZ/LOM a HR of 0.71 was observed (95%CI [0.50, 1.02]; p = 0.031 one-sided; median OS 9.6 months versus 8.2 months, 1-year OS rate 39.7% versus 28.2%). No OS difference was observed between depatux-m monotherapy (median OS 7.9 months) and TMZ/LOM (HR 1.04; 95%CI [0.73, 1.48]. In patients with relapse ≥16 weeks after end of 1stline TMZ treatment, combined depatux-m/TMZ was associated with improved OS (HR 0.45, 95%CI [0.23, 0.87]; median OS 14.9 months versus 9.5 months). The main toxicity observed in depatux-m treated patients was ocular (grade 3: 27.9%, grade 4: 1%). Although the primary endpoint was not met, depatux-m in combination with TMZ might improve OS in EGFR amplified recurrent glioblastoma. Outcome for depatux-m monotherapy was similar to LOM/TMZ control. Ocular events observed were consistent with earlier studies.
Abstract 15081: Increment of Right Atrial Pressure Influenced Occurrence of Right to Left Flow Patent Foramen Ovale and Its Relationship with Paradoxical Cerebral Infarction in Subjects with Chronic Thromboembolic Pulmonary Hypertension Considering Presence of Interatrial Septal Aneurysm
Authors: Masae Uehara, Nobusada Funabashi, Toshihiko Sugiura, Hiroyuki Takaoka, Yoshio Kobayashi
Journal: Circulation (2011)

Purpose:  To determine the clinical significance of  a  patent foramen ovale (PFO) with flow directional information and interatrial septal aneurysm (IASA) by multislice CT in subjects with pulmonary thromboembolism (PTE), we compared its incidence with right heart catheterization (RHC) findings and the occurrence of cerebral infarction (CI) detected by MRI.   Materials and Methods:  A retrospective analysis of 33 consecutive subjects (17 female; age 56±10 years) with proven chronic PTE, undergoing CT, RHC, and brain MRI. The presence of PFO with flow directional information and IASA was evaluated by enhanced CT.   Results:  PFO and IASA were detected in 13 subjects (10 right to left, 3 left to right) and 4 subjects (3 right, 1 left), respectively. Deep venous thrombus (DVT) was found in 58% and implantation of an inferior vena cava filter was performed in 97%. CI occurred in 5 subjects (all asymptomatic, age 57±10years, not significantly different from those without CI, 56±10years). Of the 10 subjects with right to left PFO, 20% had CI, not significantly different from those without PFO (15%). Of the 13 subjects with any directional PFO, 38% had CI, significantly more than those without PFO (0%, P   Conclusions:  Increased RAP from RHC may be associated with an increased incidence of any directional PFO and right to left PFO. Also, PFO may be associated with an increased occurrence of paradoxical CI in subjects with chronic PTE.
P3.02c-102 Safety and Tolerability of Abemaciclib Combined with LY3023414 or with Pembrolizumab in Patients with Stage IV NSCLC
Authors: Jonathan W. Goldman, Mariano Provencio, Shadia Jalal, Karen Kelly, Edward Kim, Ari Vanderwalde, Anwar Hossain, William John, Pilar Garrido
Journal: Journal of Thoracic Oncology (2017)
Abstract 18627: Metabolically Healthy Obesity in Patients With Coronary Artery Disease is Associated With a Favorable Vascular Phenotype and Low Risk for Cardiovascular Events: Implications for the Obesity Paradox
Authors: Alexios S Antonopoulos, Gerasimos Siasos, Vicky Tsigkou, Evangelos Oikonomou, Marina Zaromytidou, Konstantinos Mourouzis, Emmanouil Vavuranakis, George-Angelo Papamikroulis, Maria-Evi Panoilia, Nikolaos Papageorgiou, Christdoulos Stefanadis, Charis Antoniades, Dimitrios Tousoulis
Journal: Circulation (2017)

Introduction:  The obesity paradox in patients with established CAD may be explained by the paradoxically low risk of metabolically healthy obese (MHO) subjects.   Hypothesis:  MHO associates with systemic inflammation, vascular function and clinical outcome of coronary patients.   Methods:  A total of 667 CAD patients (confirmed by coronary angiography) were assessed for the presence of obesity/metabolic syndrome (MetS, waist circumference excluded) and classified as MHO (BMI≥30 &    Results:  MHO had lower IL-6 levels compared to either MUO or MUHNW, similar to that of MHNW subjects (A). MHO was also associated with lower PWV values, comparable to that of MHNW (B). There was no difference in FMD between study groups (p=NS). Gensini score was lower in MHO compared to either MUO or MUHNW, similar to that of MHNW subjects (C). Whilst increased BMI was independently associated with lower MACEs risk (b= -0.164, p=0.003) confirming the obesity paradox in these patients, this was explained by the MHO classification. MHO associated with MACEs risk (p   Conclusions:  CAD patients with MHO are characterised by low systemic inflammation, less arterial stiffness, and less severe coronary atherosclerosis comparable to that of metabolically healthy lean subjects. MHO identifies a low-risk CAD subgroup and could explain the obesity paradox in these obese patients.
The Biology of Cancer Exosomes: Insights and New Perspectives
Authors: Carolina F. Ruivo, Bárbara Adem, Miguel Silva, Sónia A. Melo
Journal: Cancer Research (2017)

Abstract Exosomes are a subclass of extracellular vesicles involved in intercellular communication that are released by all cell types, including cancer cells. Cancer exosomes carry malignant information in the form of proteins, lipids, and nucleic acids that can reprogram recipient cells. Exosomes have emerged as putative biological mediators in cancer contributing to major steps of disease progression. A leading role exists for cancer exosomes in specific aspects of tumor progression: modulation of immune response, tumor microenvironment reprogramming, and metastasis. This review will address the functions attributed to cancer exosomes in these three aspects of cancer biology, highlighting recent advances and potential limitations. Finally, we explore alternative strategies to develop better models to study cancer exosomes biology. Cancer Res; 77(23); 6480–8. ©2017 AACR.
P2.06-003 Retrospective Study of Cerebral Thromboembolism Occurring before and after Detection of Lung Cancer (Trousseau Syndrome)
Authors: K. Matsumoto, Y. Tanio, T. Yanase, K. Kuno, Y. Mitsui, Y. Shirai, M. Suzuki, J. Uchida, K. Ueno, Y. Funakoshi, H. Takabatake, S. Shimamoto, N. Tamaki, H. Fushimi, K. Shimazu
Journal: Journal of Thoracic Oncology (2017)
HIV Prevention Efforts and Incidence of HIV in Uganda
Authors: M. Kate Grabowski, David M. Serwadda, Ronald H. Gray, Gertrude Nakigozi, Godfrey Kigozi, Joseph Kagaayi, Robert Ssekubugu, Fred Nalugoda, Justin Lessler, Thomas Lutalo, Ronald M. Galiwango, Fred Makumbi, Xiangrong Kong, Donna Kabatesi, Stella T. Alamo, Steven Wiersma, Nelson K. Sewankambo, Aaron A.R. Tobian, Oliver Laeyendecker, Thomas C. Quinn, Steven J. Reynolds, Maria J. Wawer, Larry W. Chang
Journal: New England Journal of Medicine (2017)

To assess the effect of a combination strategy for prevention of human immunodeficiency virus (HIV) on the incidence of HIV infection, we analyzed the association between the incidence of HIV and the scale-up of antiretroviral therapy (ART) and medical male circumcision in Rakai, Uganda. Changes in population-level viral-load suppression and sexual behaviors were also examined.Between 1999 and 2016, data were collected from 30 communities with the use of 12 surveys in the Rakai Community Cohort Study, an open, population-based cohort of persons 15 to 49 years of age. We assessed trends in the incidence of HIV on the basis of observed seroconversion data, participant-reported use of ART, participant-reported male circumcision, viral-load suppression, and sexual behaviors.In total, 33,937 study participants contributed 103,011 person-visits. A total of 17,870 persons who were initially HIV-negative were followed for 94,427 person-years; among these persons, 931 seroconversions were observed. ART was introduced in 2004, and by 2016, ART coverage was 69% (72% among women vs. 61% among men, P<0.001). HIV viral-load suppression among all HIV-positive persons increased from 42% in 2009 to 75% by 2016 (P<0.001). Male circumcision coverage increased from 15% in 1999 to 59% by 2016 (P<0.001). The percentage of adolescents 15 to 19 years of age who reported never having initiated sex (i.e., delayed sexual debut) increased from 30% in 1999 to 55% in 2016 (P<0.001). By 2016, the mean incidence of HIV infection had declined by 42% relative to the period before 2006 (i.e., before the scale-up of the combination strategy for HIV prevention) - from 1.17 cases per 100 person-years to 0.66 cases per 100 person-years (adjusted incidence rate ratio, 0.58; 95% confidence interval [CI], 0.45 to 0.76); declines were greater among men (adjusted incidence rate ratio, 0.46; 95% CI, 0.29 to 0.73) than among women (adjusted incidence rate ratio, 0.68; 95% CI, 0.50 to 0.94).In this longitudinal study, the incidence of HIV infection declined significantly with the scale-up of a combination strategy for HIV prevention, which provides empirical evidence that interventions for HIV prevention can have a population-level effect. However, additional efforts are needed to overcome disparities according to sex and to achieve greater reductions in the incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and others.).
Development and plasticity of meningeal lymphatic vessels
Authors: Salli Antila, Sinem Karaman, Harri Nurmi, Mikko Airavaara, Merja H. Voutilainen, Thomas Mathivet, Dmitri Chilov, Zhilin Li, Tapani Koppinen, Jun-Hee Park, Shentong Fang, Aleksanteri Aspelund, Mart Saarma, Anne Eichmann, Jean-Léon Thomas, Kari Alitalo
Journal: The Journal of Experimental Medicine (2017)

The recent discovery of meningeal lymphatic vessels (LVs) has raised interest in their possible involvement in neuropathological processes, yet little is known about their development or maintenance. We show here that meningeal LVs develop postnatally, appearing first around the foramina in the basal parts of the skull and spinal canal, sprouting along the blood vessels and cranial and spinal nerves to various parts of the meninges surrounding the central nervous system (CNS). VEGF-C, expressed mainly in vascular smooth muscle cells, and VEGFR3 in lymphatic endothelial cells were essential for their development, whereas VEGF-D deletion had no effect. Surprisingly, in adult mice, the LVs showed regression after VEGF-C or VEGFR3 deletion, administration of the tyrosine kinase inhibitor sunitinib, or expression of VEGF-C/D trap, which also compromised the lymphatic drainage function. Conversely, an excess of VEGF-C induced meningeal lymphangiogenesis. The plasticity and regenerative potential of meningeal LVs should allow manipulation of cerebrospinal fluid drainage and neuropathological processes in the CNS.
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
Authors: Michael E. Weinblatt, Clifton O. Bingham, Gerd‐Rüdiger Burmester, Vivian P. Bykerk, Daniel E. Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, Brenda VanLunen, Cécile Ecoffet, Christopher Cioffi, Paul Emery
Journal: Arthritis & Rheumatology (2017)

Objective In disease‐modifying antirheumatic drug–naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both week 40 and week 52) after 1 year of treatment with certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate [MTX]), we evaluated whether continuation of CZP treatment at a standard dose or at a reduced frequency (200 mg every 4 weeks plus MTX) was superior to stopping CZP (placebo plus MTX) in maintaining low disease activity for 1 additional year. Methods A total of 293 patients from period 1 of our study were re‐randomized 2:3:2 in period 2 to CZP at a standard dose (n = 84), CZP at a reduced frequency (n = 127), or placebo plus MTX (CZP stopped) (n = 82). The primary end point was the percentage of patients who maintained low disease activity throughout weeks 52–104 without flares. We used a hierarchical testing scheme, comparing CZP at a standard dose with CZP stopped. If P &lt; 0.05 was achieved, then CZP at a reduced frequency was compared with CZP stopped (nonresponder imputation). Results The 293 patients from period 1 represented 36% fewer patients than projected, yielding a smaller number of patients eligible for period 2. Higher proportions of patients treated with the standard and reduced frequency regimens maintained low disease activity than those who had stopped CZP (48.8% and 53.2%, respectively, versus 39.2% [ P = 0.112 and P = 0.041, respectively; nominal P value, first hierarchical test not significant]). Similar trends were observed for radiographic nonprogression (change from baseline of ≤0.5 in modified Sharp/van der Heijde score; 79.2% and 77.9% of patients, respectively, versus 70.3%) and normative physical function (Health Assessment Questionnaire disability index score of ≤0.5; 71.4% and 70.6% of patients, respectively, versus 57.0%). Safety profiles were similar between all groups, with no new safety signals identified for continuing CZP to week 104. No deaths were reported. Conclusion The study failed to meet its primary end point. However, there were no clinically meaningful differences between the standard and reduced frequency doses of CZP plus MTX; both controlled RA more effectively than stopping CZP.
Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study
Authors: Hagop Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Nancy Carpenter, Bhakti Mehta, Janet Franklin, Aristoteles Giagounidis
Journal: Blood (2016)
Frequency and factors predicting the risk for aberrant opioid use in patients receiving outpatient palliative care at a comprehensive cancer center.
Authors: Sriram Yennu, Tonya Edwards, Joseph Anthony Arthur, Zhanni Lu, John M Najera, Kristy Nguyen, Eden Mae Rodriguez, Manju P Joy, Leela Kuriakose, Jimin Wu, Diane D Liu, Janet L. Williams, Suresh Reddy, Eduardo Bruera
Journal: Journal of Clinical Oncology (2017)

228 Background: Opioid misuse is a growing crisis among patients with chronic pain. Cancer patients at risk of aberrant drug behaviors (ADB) are frequently underdiagnosed in routine cancer care. The aim of this study was to determine the frequency and factors predicting risk for Aberrant Opioid and Drug use among Patients receiving Outpatient Supportive Care Consultation at a Comprehensive Cancer Center Methods: In this retrospective study, 690 consecutive patients referred to a supportive care clinic were reviewed. Patients were eligible if they were ≥18 years, had a diagnosis of cancer, and were on opioids for pain for atleast a week. All patients were assessed with the Edmonton Symptom Assessment Scale (ESAS), SOAPP-14, and CAGE-AID. At risk patients with aberrant opioid behavior (+Risk) was defined as SOAPP-14 score ≥7. Descriptive statistics, spearman correlation coefficient, multivariate analysis were performed. Results: 690/752 consults were eligible. A total of 135(20%)were +risk. 69(11%) were CAGE-AID +.SOAPP-14 scores were positively associated with CAGE-AID p &lt; 0.001; male gender p = 0.007; ESAS pain p = &lt; 0.006; ESAS depression p &lt; 0.001; ESAS anxiety, p &lt; 0.001, and ESAS financial distress p = &lt; 0.001. Multivariate analysis indicated that the odds ratio for +Risk was 2.47 in patients with CAGE-AID+ (p &lt; 0.001), 1.95 for male gender (p = 0.005), 1.11 per point for ESAS anxiety (p = 0.019), and 1.1 per point. for ESAS financial distress (p = 0.02). Conclusions: 20% of cancer patients on opioids presenting to supportive care center are at risk of aberrant drug behavior. Male patients with anxiety, financial distress, and prior alcoholism/illicit drug use are significant predictors of +Risk. Further research to effectively manage these patients is needed.
P2.03a-015 Systemic Inflammation Alters Carboplatin Pharmacokinetics Explaining Poor Survival in Advanced Lung Cancer Patients
Authors: Benjamin Harris, Viet Phan, Vidya Perera, Anneliese Szyc, Peter Galettis, Philip Beale, Andrew Mclachlan, Stephen Clarke, Kellie Charles
Journal: Journal of Thoracic Oncology (2017)
Situation en France par rapport au variant suédois de Chlamydia trachomatis
Authors: B de Barbeyrac, S Raherison, S Cado, F Normandin, M Clerc, V Clairet, V Goulet, C Bébéar
Journal: Eurosurveillance (2007)

En 2006, un mutant de Chlamydia trachomatis presentant une deletion sur son plasmide a ete identifie en Suede ; ce variant ne peut etre detecte par les tests existants qui ciblent la zone deletee. Afin d’etudier la propagation de cette souche en France, un systeme de surveillance en laboratoire a ete mis en place par le Centre national de reference des infections a Chlamydiae et l’Institut de veille sanitaire.